Revenue
2022
2023
2024
2025
Cellbxhealth plc (CLBX)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £1.4M | £2.9M | £2.2M | £1.0M |
| Research & development | £1.3M | £1.8M | £2.5M | £4.0M |
| Operating expenses | £16.2M | £17.3M | £22.0M | £26.7M |
| Operating income | −£15.4M | −£15.5M | −£20.5M | −£26.1M |
| Operating margin | −1,140.04% | −540.74% | −935.86% | −2,508.07% |
| EBITDA | −£13.5M | −£13.0M | −£19.0M | −£21.2M |
| EBITDA margin | −1,000.96% | −455.07% | −869.12% | −2,041.02% |
| Net income | −£19.5M | −£14.2M | −£20.1M | −£21.7M |
| Net profit margin | −1,444.04% | −497.03% | −920.95% | −2,083.19% |
| Basic EPSper basic share | -£0.06 | -£0.05 | -£0.08 | -£0.09 |
| Diluted EPSper diluted share | -£0.06 | -£0.05 | -£0.08 | -£0.09 |